Insiders · ATOS

Mark James Daniel

Chief Financial Officer at Atossa Therapeutics, Inc. (ATOS) since October 2025

Mark James Daniel has filed 3 insider reports with the SEC since October 2025, as chief Financial Officer at Atossa Therapeutics, Inc. (ATOS). The latest filing, on March 30, 2026, reports grant or award at Atossa Therapeutics, Inc. (ATOS).

Filings
3
Companies
1
Bought on market
None
Sold on market
None

Companies where Mark James Daniel is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Atossa Therapeutics, Inc. logo
ATOS
Atossa Therapeutics, Inc.
Chief Financial Officersince October 202563,000$1.595Mar 30, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Mark James Daniel with

Other insiders at the same companies

Questions about Mark James Daniel

What is Mark James Daniel's role at Atossa Therapeutics, Inc.?
Mark James Daniel reports to the SEC as chief Financial Officer at Atossa Therapeutics, Inc. (ATOS), according to the latest filing on March 30, 2026.
How many shares does Mark James Daniel own?
After the latest filing that states it, Mark James Daniel directly owned 63,000 shares of Atossa Therapeutics, Inc. (ATOS). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Mark James Daniel bought or sold stock recently?
No open-market purchases or sales by Mark James Daniel are on file. The filings report grant or award.
How do I get alerts when Mark James Daniel files?
Follow Mark James Daniel on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Mark James Daniel (SEC CIK 0002092593). Totals count each trade once, skipping amendments whose original is on file, from Oct 21, 2025 on. View on SEC EDGAR · Get this as JSON